Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Metadata
Title
Vascular endothelial growth factor in ovarian cancer
Authors
Darcie A. Hazelton, PhD
Thomas C. Hamilton, PhD
Publication date
01-03-1999
Publisher
Current Medicine Group
Published in
Current Oncology Reports / Issue 1/1999
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-999-0011-9

Other articles of this Issue 1/1999

Current Oncology Reports 1/1999 Go to the issue

OriginalPaper

Dose-intensive approaches to ovarian cancer

OriginalPaper

Systemic therapy for advanced or recurrent endometrial carcinoma

Editor’s Commentary

“Clinical benefit” following treatment with antineoplastic drugs: What does it mean and how should we measure it?

Abstract

Literature alert

OriginalPaper

In vitro chemosensitivity testing and mechanisms of drug resistance

OriginalPaper

Salvage therapy for ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits